Velcade is a cancer medicine that is generally used in combination with other medicines to treat multiple myeloma, a blood cancer, in: - adults whose disease is getting worse after at least one other treatment and who have already had blood stem-cell transplantation or cannot have it. In these patients, Velcade is used either on its own or with pegylated liposomal doxorubicin or dexamethasone; - previously untreated adults who cannot have high-dose chemotherapy with blood stem-cell transplantation. In these patients, Velcade is used in combination with melphalan and prednisone; - previously untreated adults who are going to receive high-dose chemotherapy followed by a blood stem-cell transplantation. In these patients, Velcade is used in combination with dexamethasone, or with dexamethasone plus thalidomide. Velcade is also used to treat mantle cell lymphoma, another blood cancer. It is used in adults who have not received any treatment for their cancer and who cannot have blood stem-cell transplantation. In these patients Velcade is used with rituximab, cyclophosphamide, doxorubicin and prednisone. Velcade contains the active substance bortezomib.
Therapeutic Indication
### Therapeutic indication Velcade as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation. Velcade in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high dose chemotherapy with haematopoietic stem cell transplantation. Velcade in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high dose chemotherapy with haematopoietic stem cell transplantation. Velcade in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.
Therapeutic Area (MeSH)
ATC Code
L01XG01
ATC Item
bortezomib
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| bortezomib | N/A | 硼替佐米 |
EMA Name
Velcade
Medicine Name
Velcade
Aliases
N/A